Syndax Pharmaceuticals (Nasdaq: SNDX), a US-based clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced on Friday updated data from multiple combination trials of revumenib, the company's potent, selective, small molecule menin inhibitor, in patients with acute leukaemia.

The updated data were presented at the European Hematology Association (EHA) 2024 Congress in Madrid, Spain, and virtually.

'The growing body of data supports the potential for revumenib to have a meaningful impact in combination with current standard of care therapies,' said Joshua F. Zeidner, M.D., chief, Leukemia Research at the University of North Carolina, Lineberger Comprehensive Cancer Center. 'Based on the BEAT AML data in the newly diagnosed setting which showed a high rate of MRD-negative responses coupled with a safety profile that enables combination use, revumenib has the potential to become a cornerstone of treatment as front-line therapy for newly diagnosed KMT2Ar and mNPM1 AML.'

'We are committed to advancing revumenib across a spectrum of acute leukaemia patients. As we prepare for the expected near-term approval of revumenib in the relapsed or refractory setting, we look forward to providing additional clinical data as monotherapy and in combination to support treatment in various acute leukaemia treatment settings where novel treatment options are urgently needed,' said Neil Gallagher, M.D., Ph.D., president, head of Research and Development at Syndax.